Recurrence Pattern in Localized RCC: Results from a European Multicenter Database (RECUR) - Beyond the Abstract

Minimally invasive surgery (MIS) for kidney cancer treatment has been introduced with success over the past 30 years. Currently, it is the most frequently used approach.1,2 Over the years some reports claimed for increased risk of uncommon site recurrences after MIS, such as port sites and intraperitoneal carcinomatosis. However, the debate is still open.3,4 Recently, data from the Memorial Sloan Kettering Cancer Center (New York, NY, USA) regarding 58 patients with kidney cancer submitted to MIS (radical or partial nephrectomy) between 1999 to 2021 and who developed uncommon sites recurrences further reinforced this hypothesis.5

Using data from the RECUR (euRopEan association of urology renal cell carcinoma guidelines panel Collaborative multicenter consortium for the studies of follow-Up and recurrence patterns in Radically treated renal cell carcinoma patients) consortium we assessed the risk of uncommon site metastasis in a cohort of 1019 patients submitted to MIS for kidney cancer matched with a cohort of 1019 patients submitted to open surgery for kidney cancer.

The two cohorts of patients with pT1-3aN0M0 renal cell carcinoma were matched for surgery, gender, clinical tumor size, year of surgery and surgical case load, to account for possible confounders. We found that patient submitted to MIS were at higher risk of local recurrence (i.e., renal recurrence in the resection bed after PN and in the renal fossa following RN) - HR 2.06; 95% CI 1.18-3.58, p-value=0.01- and of uncommon site metastasis (e.g. disseminated metastases, bone, brain, thyroid gland, skin and all the other sites not included in the previous categories, outside thoracic or abdominal cavity) - HR 1.09; 95% CI 1.01-1.16; p-value=0.04. Most of the MIS cohort patients were submitted to laparoscopic PN or RN, whereas only 70 patients to a robot-assisted approach. Of note, overall survival and cancer specific survival were similar between the two groups.

The validity of this study relies on the use of the large multi-center RECUR database with long follow-up and granular data from top European academic centers for kidney surgery. The study is hypothesis generating and more solid literature on this topic is warranted, in particular regarding robotic cases. Our findings should encourage further research on the topic to maximise surgical and oncological outcomes for our patients.

Written by: Giuseppe Fallara, MD & Umberto Capitanio, MD, Division of Experimental Oncology/Unit of Urology; URI; IRCCS Ospedale San Raffaele, Milan, Italy

References:

  1. Klingler DW, Hemstreet GP, Balaji KC. Feasibility of robotic radical nephrectomy—initial results of single-institution pilot study. Urology 2005;65(6):1086–9.
  2. Patel HD, Mullins JK, Pierorazio PM, Jayram G, Cohen JE, Matlaga BR, et al. Trends in Renal Surgery: Robotic Technology is Associated with Increased Use of Partial Nephrectomy. J Urology 2013;189(4):1229–35.
  3. Song J, Kim E, Mobley J, Vemana G, Tanagho Y, Vetter J, et al. Port Site Metastasis after Surgery for Renal Cell Carcinoma: Harbinger of Future Metastasis. J Urology 2014;192(2):364–8.
  4. Castillo OA, Vitagliano G. Port Site Metastasis and Tumor Seeding in Oncologic Laparoscopic Urology. Urology 2008;71(3):372–8.
  5. Russo P, Blum KA, Weng S, Graafland N, Bex A. Outcomes for Atypical Tumor Recurrences Following Minimally Invasive Kidney Cancer Operations. European Urology Open Sci 2022;40:125–32.
Read the Abstract